EGFR and lung adenocarcinoma: The LUX-Lung 7 trial reported that afatinib used as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations significantly prolonged PFS and the time to treatment failure but not overall survival compared to gefitinib treatment [10].